ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Randomized Trial"

  • Abstract Number: 0502 • ACR Convergence 2024

    Similar Efficacy, PK, Safety, and Immunogenicity of Tocilizumab Biosimilar (CT-P47) and Reference Tocilizumab in Patients with Moderate-to-Severe Active Rheumatoid Arthritis: Week 52 Results from the Phase III Single Transition Study

    Gerd Burmester1, Jakub Trefler2, Artur Racewicz3, Janusz Jaworski4, Agnieszka Zielińska5, Marek Krogulec6, Sławomir Jeka7, Rafał Wojciechowski8, Katarzyna Kolossa9, Anna Dudek10, Magdalena Krajewska-Włodarczyk11, Paweł Hrycaj12, Piotr Adrian Klimiuk13, SungHyun Kim14, JeeHye Suh14, GoEun Yang14, Yunah Kim14, YooBin Jung14, JiWoo Hong14 and Josef Smolen15, 1Department of Rheumatology and Clinical Immunology, Charité – Universitätsmedizin Berlin, Berlin, Germany, 2REUMA RESEARCH, Wrocław, Poland, 3Zdrowie Osteo-Medic, Warszawa, Poland, 4Reumatika-Centrum Reumatologii, Warszawa, Poland, 5MICS Centrum Medyczne Warszawa, Warszawa, Poland, 6NZOZ Lecznica MAK - MED, Nadarzyn, Poland, 7MICS Centrum Medyczne, Polska, Poland, 8Department of Rheumatology and Systemic Connective Tissue Diseases, University Hospital No. 2, Bydgoszcz, PL, Bydgoszcz, Poland, 9MICS Centrum Medyczne Bydgoszcz, Bydgoszcz, Poland, 10Centrum Medyczne Amed, Warszawa, Poland, 11University of Warmia and Mazury, Clinic of Rheumatology, Olsztyn, Poland, 12Prywatna Praktyka Lekarska Prof. dr hab. med. Paweł, Poznań, Poland, 13Medical University of Bialystok and Inter Clinic Piotr Adrian Klimiuk, Department of Rheumatology and Internal Diseases, Białystok, Poland, 14Celltrion, Inc., Incheon, Republic of Korea, 15Medical University of Vienna, Vienna, Austria

    Background/Purpose: The therapeutic equivalence of CT-P47 (a proposed biosimilar to reference tocilizumab [ref-tocilizumab]) was demonstrated in patients with moderate to severe RA through disease activity…
  • Abstract Number: 1427 • ACR Convergence 2024

    Observed and Simulated Pharmacokinetics and Pharmacodynamics of Nipocalimab, a Fully Human FcRn Blocking Monoclonal Antibody, in Adults with Sjögren’s Disease: Results from a Phase 2, Multicenter, Randomized, Placebo-controlled, Double-blind Study

    Sophia G. Liva1, fudan Zheng1, Jocelyn H. Leu2, Kathy Sivils3, Keying Ma1, He Li4, Steven Leonardo5, Kim Lo1, Jada Idokogi1, Kim Campbell1 and Jonathan J. Hubbard1, 1Janssen Research & Development, LLC, a Johnson & Johnson Company, Spring House, PA, 2Janssen Research & Development, LLC, a Johnson & Johnson company, Spring House, PA, PA, 3Johnson & Johnson Innovative Medicine, Edmond, OK, 4Janssen Research & Development, LLC, Therapeutics Discovery, Spring House, PA, 5Janssen Research & Development, LLC, a Johnson & Johnson Company, Cambridge, MA

    Background/Purpose: Sjögren’s disease (SjD) is a chronic, progressive autoimmune disease characterized by aberrant B lymphocyte activity, elevated IgG production, and the presence of IgG autoantibodies…
  • Abstract Number: 1605 • ACR Convergence 2024

    Characteristics of Relapses in Patients with Eosinophilic Granulomatosis with Polyangiitis

    Peter Merkel1, David Jayne2, Ulrich Specks3, Christian Pagnoux4, Parameswaran Nair5, Nader Khalidi5, Arnaud Bourdin6, Lena Börjesson Sjö7, Sofia Necander7, Anat Shavit8, Claire Walton9 and Michael Wechsler10, 1University of Pennsylvania, Philadelphia, PA, 2University of Cambridge, Cambridge, United Kingdom, 3Mayo Clinic, Rochester, MN, 4Mount Sinai Hospital, Toronto, ON, Canada, 5McMaster University and St Joseph’s Healthcare, Hamilton, ON, Canada, 6Department of Respiratory Diseases, University of Montpellier, CHU Montpellier, PhyMedExp, INSERM, CNRS, Montpellier, France, 7Late-Stage Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden, 8BioPharmaceuticals Medical, AstraZeneca, Cambridge, United Kingdom, 9Late-Stage Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom, 10National Jewish Health, Denver, CO

    Background/Purpose: Eosinophilic granulomatosis with polyangiitis (EGPA) is a rare inflammatory disorder characterized by asthma, eosinophilia, and small-to-medium size vessel vasculitis. In the Phase 3, double-blind,…
  • Abstract Number: 2101 • ACR Convergence 2024

    Patient Characteristics Associated with Objectively-Assessed Physical Activity in Veterans with Knee Osteoarthritis

    Hannah Brubeck1, David Azizi2, Sarah Wetzel2, Marianna Olave2, Rachel Gillcrist3, Bridget Kramer4, Bibiana Ateh5, Daniel White6, Carla Scanzello7, Tuhina Neogi8, Alexis Ogdie9, Bryant England4, Mercedes Quinones10, Katherine Wysham11 and Joshua Baker7, 1VA Puget Sound Health Care System, Seattle, WA, 2Corporal Michael J. Crescenz VA Medical Center, Philadelphia, PA, 3Corporal Michael J. Crescenz VA Medical Center, Philadelphia, 4University of Nebraska Medical Center, Omaha, NE, 5Washington DC VA Medical Center, Washington, DC, 6University of Delaware, Newark, DE, 7University of Pennsylvania, Philadelphia, PA, 8Boston University Chobanian & Avedisian School of Medicine, Boston, MA, 9Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, 10Washington DC VA Medical Center, Bethesda, MD, 11VA PUGET SOUND/UNIVERSITY OF WASHINGTON, Seattle, WA

    Background/Purpose: Despite strong recommendations for physical activity in knee osteoarthritis (KOA) clinical practice guidelines, only a small fraction of those with KOA meet guidelines for…
  • Abstract Number: 2367 • ACR Convergence 2024

    Updated Long-Term Safety and Tolerability of Bimekizumab in Patients with Axial Spondyloarthritis and Psoriatic Arthritis: Pooled Results from Phase 2b/3 Studies

    Philip Mease1, Denis Poddubnyy2, Rajan Bajracharya3, Barbara Ink3, Alexander Marten4, Ute Massow4, Vishvesh Shende3, Myriam Manente5, Luke Peterson6, Katy White3, Peter Nash7 and Lianne S Gensler8, 1Swedish Medical Center/Providence St. Joseph Health; University of Washington School of Medicine, Seattle, WA, 2Charite-Universitatsmedizin Berlin, Berlin, Germany, 3UCB Pharma, Slough, United Kingdom, 4UCB Pharma, Monheim am Rhein, Germany, 5UCB Pharma, Braine-l'Alleud, Belgium, 6UCB Pharma, Morrisville, NC, 7School of Medicine, Griffith University, Sunshine Coast, Queensland, Australia, 8Department of Medicine/Rheumatology, University of California, San Francisco, San Francisco, CA

    Background/Purpose: Bimekizumab (BKZ) is a monoclonal IgG1 antibody that selectively inhibits interleukin (IL)‑17F in addition to IL‑17A. BKZ was generally well tolerated by patients (pts)…
  • Abstract Number: 0525 • ACR Convergence 2024

    Assess the Effect of Increasing the Dose of Folic Acid Supplementation in Patients of Rheumatoid Arthritis with Methotrexate Intolerance – A Randomised Controlled Trial

    Varun Dhir1, Harshith Sai Koneti2, Aman Sharma3, sanjay jain4 and shankar naidu5, 1PGIMER, CHD, INDIA, CHANDIGARH, India, 2PGIMER, Chandigarh, Sangareddy, Telangana, India, 3PGIMER, Chandigarh, India, Chandigarh, Chandigarh, India, 4PGIMER, Chandigarh, Chandigarh, India, 5PGIMER, Chandigarh, India, Chandigarh, India

    Background/Purpose: : Methotrexate (MTX) Intolerance continues to occur in 20-40% patients despite low-dose folic acid (5-10mg per week) supplementation. Would a higher dose of folic…
  • Abstract Number: 1428 • ACR Convergence 2024

    A Post-hoc Analysis of Two Phase 2 Randomized Controlled Trials in Patients with Active Sjogren’s Disease Exploring the Novel Composite Endpoint Sjögren’s Tool for Assessing Response (STAR)

    Wolfgang Hueber1, Raphaele Seror2, Raphael Porcher3, Gabriel Baron4, Linchen He5, Wen-Lin Luo5, Xavier Mariette6 and Peter Gergely1, and the members of the NECESSITY IMI2 consortium, 1Novartis Pharma, Basel, Switzerland, 2Service de Rhumatologie, Hôpital Bicêtre, AP-HP, le Kremlin Bicetre, Ile-de-France, France, 3Department of Rheumatology, Bicêtre AP-HP Hôpital, Université Paris-Saclay, Paris, Ile-de-France, France, 4Hôpitaux Universitaires Paris-Sud (AP-HP), Paris, Ile-de-France, France, 5Novartis Pharma, East Hanover, NJ, 6Service de Rhumatologie, Hôpital Bicêtre, AP-HP, Le Kremlin Bicetre, France

    Background/Purpose: Two randomized controlled phase 2 trials in patients with active Sjogren’s disease (SjD) were recently completed, the LOUiSSe trial assessing the Bruton Tyrosine kinase…
  • Abstract Number: 1665 • ACR Convergence 2024

    Multicenter Randomized Controlled Trial of Physical Therapy (PT) or Sham PT in Persons with Knee Pain, Meniscal Tear, and Osteoarthritic Imaging Changes

    Jeffrey Katz1, Jamie Collins2, Leslie Bisson3, Faith Selzer4, Morgan Jones2, Heidi Yang2, James Irrgang5, Clare Safran-Norton2, Kurt Spindler6 and Elena Losina2, 1Brigham and Women's Hospital, Brookline, MA, 2Brigham and Women's Hospital, Boston, MA, 3University at Buffalo, Buffalo, NY, 4Brigham and Women's Hospital, Amesbury, MA, 5University of Pittsburgh, Pittsburgh, PA, 6Cleveland Clinic, Clev, OH

    Background/Purpose: The syndrome of knee pain and meniscal tear (MT) is prevalent and disabling. The TeMPO trial (Treatment of Meniscal Problems in Osteoarthritis (OA)) compares…
  • Abstract Number: 2113 • ACR Convergence 2024

    Discontinuation and Non-publication of Postmenopausal Osteoporosis Clinical Studies: A Cross-sectional Analysis of 345,435 Patients

    Mohamed Abdelsalam1, yasmeen Alabdallat2, Yousef Hussein3, Mona Sajed4, Maryam Taha5, Rawan morse6, Wessam Selima7 and Ahmed Zabady8, 1Rheumatology, Rehabilitation and Physical medicine department - faculty of medicine -Misr University for science and technology, 6th of October, Al Jizah, Egypt, 2Faculty of medicine - Hashemite university, Zarqa, Jordan, 3Faculty of medicine - Benha university, Benha, Egypt, 4Faculty of Pharmacy - Al-Azhar university for girls, Mansoura, Ad Daqahliyah, Egypt, 5Faculty of medicine - Ain Shams university, Madinat Nasr, Al Qahirah, Egypt, 6Medical Research Group of Egypt, Bur sa'id, Egypt, 7Anaesethia & pain management department, Faculty of medicine, Ain Shams University, Cairo, Egypt, 8Faculty of science - Damanhour university, Cairo, Egypt

    Background/Purpose: Postmenopausal osteoporosis (PMOP) significantly contributes to global fracture rates annually, with its silent progression complicating early detection and intervention. Effective management strategies are crucial,…
  • Abstract Number: 2369 • ACR Convergence 2024

    Impact of Baseline Factors on Disease Progression and Apremilast Efficacy in Early Oligoarticular Psoriatic Arthritis

    Philip Mease1, Laura Coates2, Alexis Ogdie3, Dafna Gladman4, Alen Zabotti5, Xenofon Baraliakos6, Cynthia Deignan7, Shauna Jardon7, Rebecca Wang7, Lichen Teng7 and Laure Gossec8, 1Swedish Medical Center/Providence St. Joseph Health; University of Washington School of Medicine, Seattle, WA, 2University of Oxford, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, Oxford, United Kingdom, 3Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, 4University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, 5Azienda Sanitaria Universitaria del Friuli Centrale, Udine, Udine, Italy, 6Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Herne, Germany, 7Amgen Inc., Thousand Oaks, CA, 8Sorbonne Université, Paris, France

    Background/Purpose: In the FOREMOST study of early oligoarticular psoriatic arthritis (PsA), fewer patients (pts) receiving apremilast (APR) progressed from ≤4 active joints (all joints; oligoarthritis)…
  • Abstract Number: 0533 • ACR Convergence 2024

    Using Adalimumab Serum Concentration to Choose a Subsequent DMARD in Rheumatoid Arthritis Patients Failing Adalimumab Treatment (ADDORA-switch): Results of a Blinded Randomized Test Treatment Trial

    Maike Wientjes1, Sadaf Atiqi2, Gertjan Wolbink3, Michael Nurmohamed4, Maarten Boers5, Femke Hooijberg2, Theo Rispens6, Annick De Vries6, Floris Loeff6, Ronald Van Vollenhoven7, Sofia Ramiro8, Noortje van Herwaarden9, Bart van den Bemt10 and Alfons den Broeder1, 1Sint Maartenskliniek, Ubbergen, Netherlands, 2Reade, Amsterdam, Netherlands, 3Reade and Sanquin Diagnostic Services, Amsterdam, Netherlands, 4Reade and Amsterdam UMC, Kortenhoef, Netherlands, 5Amsterdam UMC, Vrije Universiteit, Amersfoort, Netherlands, 6Sanquin Diagnostic Services, Amsterdam, Netherlands, 7Department of Rheumatology and Clinical Immunology, Amsterdam University Medical Centers, Amsterdam, Netherlands, 8Leiden University Medical Center, Bunde, Netherlands, 9Sint Maartenskliniek, Nijmegen, Netherlands, 10Sint Maartenskliniek / Radboudumc, Ubbergen, Netherlands

    Background/Purpose: Adalimumab is an effective and safe treatment for RA, however a substantial proportion of RA patients discontinue its use due to inefficacy. Upon failure,…
  • Abstract Number: 1458 • ACR Convergence 2024

    Synovial Transcriptomic Sex-Specific Differences in the Response to Biologics in Psoriatic Arthritis Patients

    Pauline KRUG1, angela De Sousa Leite2, Frédéric Lecouvet1, Maria Simona stoenoiu1 and Adrien Nzeusseu Toukap3, 1Cliniques universitaires St-Luc, Brussel, Belgium, 2Cliniques universitaires St-Luc, Brussels, Belgium, 3Cliniques universitaires Saint-Luc,, St.-Lambrechts-Woluwe, Belgium

    Background/Purpose: Psoriatic arthritis (PsA) is a highly heterogeneous disease. The response to therapy is variable among patients (ref.). Therefore, we need a tailored approach. Biologic…
  • Abstract Number: 1666 • ACR Convergence 2024

    Preliminary Effects of a Fully-Remote Online Physical Activity Program Following Knee Replacement

    Scott Jamieson1, Jessica Unick2, Kailyn Horn1, Halle Prine1, Chih-Hsiang Yang1 and Christine Pellegrini1, 1University of South Carolina, Columbia, SC, 2Brown Alpert Medical School at Brown University, Providence, RI

    Background/Purpose: After knee replacement (KR), most adults fail to meet recommended levels of physical activity. Virtual options to promote physical activity in clinical populations have…
  • Abstract Number: 2144 • ACR Convergence 2024

    Impact of Immunogenicity on Clinical Outcomes in Postmenopausal Women with Osteoporosis: Results from a Randomized Controlled Phase 3 Study to Compare CT-P41 (Proposed Denosumab Biosimilar) and Reference Denosumab

    Jean-Yves Reginster1, Stuart L. Silverman2, Edward Czerwinski3, Przemyslaw Borowy4, Tomasz Budlewski5, Joanna Kwiatek6, Svitlana Postol7, Airi Põder8, Jerzy Supronik9, SungHyun Kim10, JeeHye Suh10, GoEun Yang10, NooRi Han10, NaHyun Kim10 and SeoHee Bae10, 1Biochemistry Dept, College of Science, King Saud University, Riyadh, Kingdom of Saudi Arabia, CLARENS, Switzerland, 2OMC clinical research center and Cedars Sinai Medical Center, Beverly Hills, CA, 3Krakowskie Centrum Medyczne, Kraków, Poland, 4Krakowskie Centrum Medyczne, Krakow, Poland, 5Department of Rheumatology, Medical University of Lodz, Lodz, Poland, 6Centrum Medyczne Poznan - PRATIA, Skorzewo, Poland, 7Medical Center of Medbud - Clinic LLC, Kyiv, Ukraine, 8Clinical Research Centre Ltd, Tartu, Estonia, 9Osteo-Medic s.c., Białystok, Poland, 10Celltrion, Inc., Incheon, Republic of Korea

    Background/Purpose: CT-P41 has been developed as a proposed biosimilar of the reference denosumab (DEN), a fully human monoclonal antibody that binds the cytokine receptor activator…
  • Abstract Number: 2402 • ACR Convergence 2024

    Belimumab Reduces Disease Flares versus Placebo in Adults with Early Active Systemic Lupus Erythematosus: Results of a Large Integrated Analysis

    Marta Mosca1, Karen Costenbader2, Joan Merrill3, Holly Quasny4, Christine Henning5, Steven Bloom6, Julia Harris6, Ciara O’Shea7, Tatsuya Atsumi8 and Ronald Van Vollenhoven9, 1University of Pisa, Department of Clinical and Experimental Medicine - Rheumatology Unit, Pisa, Italy, 2Brigham and Women's Hospital/ Harvard Medical School, Boston, MA, 3Oklahoma Medical Research Foundation, Oklahoma City 73104, OK, 4GSK, Clinical Sciences, Durham, NC, 5GSK, Global Medical Affairs, Durham, NC, 6GSK, Immunology Biostatistics, Brentford, United Kingdom, 7GSK, Rheumatology, Global Medical Affairs, Dublin, Ireland, 8Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan, Sapporo, Japan, 9Department of Rheumatology and Clinical Immunology, Amsterdam University Medical Centers, Amsterdam, Netherlands

    Background/Purpose: SLE flares are associated with increased risk of organ damage/mortality; flare prevention is a key treatment goal.1 Initiating treatment earlier has benefits in autoimmune…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • …
  • 19
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology